BioSpace News Archive

PROCEPT BioRobotics® Corporation, a surgical robotics global leader, is pleased to announce that the National Institute for Health and Care Excellence has bestowed its strongest endorsement, the “standard arrangements” recommendation, on Aquablation® therapy for the treatment of benign prostatic hyperplasia.

Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its third quarter 2023 financial results on Thursday, Nov. 2, after market close.

Kuros Biosciences, a leader in next-generation bone graft technologies, provides an update on its commercial activities for the first nine months of 2023 and announces changes and a transition in responsibilities within the Executive Management.

SystImmune, Inc announced that the first patient was treated on October 10th, 2023 with BL-B01D1, a first-in-class bispecific antibody-drug conjugate targeting both EGFR and HER3, as part of the global, multi-center Phase 1 study, BL-B01D1-LUNG-101, that is underway to evaluate the safety, tolerability, and efficacy of BL-B01D1 in individuals with Metastatic or Unresectable Non-Small Cell Lung Cancer.

AlzeCure Pharma AB announced that the company’s presentation at the pain conference held by the Swedish Pain Society is now available in its entirety on the company’s website.

Coave Therapeutics announces the formation of its new Scientific Advisory Board (SAB) comprising renowned leaders in gene therapy, neurological diseases, adeno-associated viral (AAV) and non-viral vector technologies.

Olema Pharmaceuticals, Inc. today announced new preclinical data regarding the discovery of novel compounds targeting KAT6, an epigenetic target that is dysregulated in breast and other cancers.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the closing of an exclusive license agreement with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio) and an associated investor for the development of motixafortide across all indications in Asia.

MediLink Therapeutics (“MediLink”), announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE.

ClearB Therapeutics, Inc. announced that the first patient has been dosed in the Phase 1b clinical study evaluating the therapeutic vaccine CLB-3000.